Ataraxis AI
New York, New York, United States · Information Technology · 7 employees
Ataraxis is an AI precision medicine company transforming cancer diagnostics and patient outcomes through the power of AI. We are addressing previously unsolvable problems in cancer prognosis and treatment selection through cutting-edge foundation models and multi-modal data. Our first clinically validated offering, Ataraxis Breast, is the world’s first AI-native prognostic/predictive test for
Funding history
- Funding Round — $20.0M — Jan 2025
Recent signals
- Jan 05, 2026: Ataraxis AI and Unicancer Partner to Validate Ataraxis™ Breast Prognostic Tool Using Global Phase III Trial Data.
- Jan 03, 2025: Raised $20.0M
See plans & pricing → Track Ataraxis AI’s funding, hiring, and signals — with verified contacts — on Fundz.